![](https://molekuleconsulting.com/wp-content/uploads/2020/10/US-Drawing.svg)
Molekule’s Specific U.S. Capabilities
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/1-4.svg)
Molekule is headquartered in Miami, FL and has strategically positioned offices in New York City and New Jersey.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/2-4.svg)
Molekule consultants solely conduct ethical, elicitation-style competitive intelligence primary research - neither honorarium, nor compensation are rendered to respondents. All conversations are non-transactional.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/3-4.svg)
The U.S.-market and U.S.-headquartered biopharma represent ~50% of Molekule’s total annual workload.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/4-4.svg)
Molekule annually conducts more than 60 U.S.-based primary research projects and 15+ competitive simulations - the team also attends 50+ U.S. congresses across therapy areas and subject matters.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/5-4.svg)
Our U.S.-team understands the nuances of U.S.-market pricing & market access, regulatory, go-to-market strategy, field force sizing and structure and generics & biosimilars - we are therefore, well-positioned to support.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/EU-Drawing.svg)
Molekule’s Specific European Capabilities
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/1-4.svg)
Molekule established its European HQ in 2017 to specifically serve the European market.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/2-5.svg)
Molekule has conducted 27 projects in the last 12 months in Europe covering EU5, Nordic countries, Eastern European countries, Switzerland, and others.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/3-5.svg)
Molekule consultants are “fluent” in 17 languages and therefore can conduct most primary CI interviews in the native language of the person interviewed.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/4-5.svg)
Molekule has in-house consultants on the ground in many of the major European countries.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/5-5.svg)
Today, 40% of Molekule’s work is for European companies and/or focus is the European market.
![](https://molekuleconsulting.com/wp-content/uploads/2020/11/LATAM-Drawing.svg)
Molekule Consulting's LATAM Engagement Experience
Molekule maintains a highly granularized and dialed-in perspective regarding the LATAM biopharmaceutical market - commercial/marketing, regulatory/technical, clinical/medical and manufacturing/supply chain logistics - in support of our client partners.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/1-5.svg)
Understanding the regulatory, manufacturing and supply chain logistics, clinical and commercial dynamics of LATAM-based biosimilars players for three (3) key oncology biologic assets in key markets (Argentina, Brazil, Bolivia, Chile, Cuba, Mexico, Venezuela)
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/2-6.svg)
Targeted due diligence and threat assessment of Brazil-based local, regional and extra-regional (i.e.- MNC biopharmaceutical companies with a presence in Brazil) biopharmaceutical players and their intentions to establish distribution hubs/nodes in the Brazil market
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/3-6.svg)
Due diligence assessment: a Brazil-based Biotech, a Mexico Based Biotech, and a Russia-based Biotech as potential LATAM alliance partners and/or M&A targets
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/4-6.svg)
Elucidation of local-MNC partnerships among LATAM-based biopharmaceutical players and potential and/or realized MNC pharmacos
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/5-6.svg)
Competitive intelligence assessment of the LATAM generics and innovator small molecule pharmaceutical market in Argentina, Brazil, Cuba and Mexico
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/6-4.svg)
Regulatory assessment of ANVISA’s “risk tolerance appetite” for MNC biopharmaceutical companies’ regulatory dossiers and forecasting of the subsequent pricing & reimbursement of these assets, forward-looking
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/7-5.svg)
Targeted assessment: Fiocruz (Bio-Manguinhos) and its vaccines and biosimilars capabilities for the LATAM market
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/ASIA-Drawing.svg)
Our Deep and Significant Experience In Asia-Pacific (“A-P”) and Asean Markets
A Select View of Molekule’s A-P AND ASEAN FOCUSED Engagements
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/1-6.svg)
Determining the competitive threat of a China-based biopharmaceutical player with respect to its anti VEGF ophthalmology asset; a focused assessment of ex-China opportunity, strategic intent and tactical implementation
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/2-7.svg)
Focused assessment of a mid-sized Japan-based pharmaceutical player to determine ex-Japan strategic intentions with respect to a high potential developmental biosimilar asset
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/3-7.svg)
Targeted assessment of ASEAN local and regional diabetes players: how will diabetes competitors leverage a portfolio of both injectable and oral antidiabetic agents to drive an extra-regional Asia-Pacific strategy.
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/4-7.svg)
Deep dive assessment of emerging Asia-Pacific markets – Thailand, Malaysia, China, S. Korea, Vietnam and Cambodia – MNC biopharmas’ strategic intent, tactical implementation and overt mid-range strategic plans
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/5-7.svg)
Comprehensive assessment of emerging Korea-based biosimilars competitors: determining developmental portfolio strategies & priorities, partnerships & tie-ups and long-range commercialization plans
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/6-5.svg)
Understanding the emerging novel anti-viral market in key Tier II/Tier III ASEAN and Asia-Pacific markets
![](https://molekuleconsulting.com/wp-content/uploads/2020/10/7-6.svg)
Comprehensive landscape monitoring of diosgenin and androstenedione manufacturing, distribution, wholesale, trade and resale in Asia-Pacific markets